Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2025—Beckman Coulter Diagnostics announced that its DxC 500i clinical analyzer received FDA 510(k) clearance. The integrated chemistry and immunoassay analyzer has a throughput of up to 800 clinical chemistry tests and 100 immunoassay tests per hour and features FlexMode operations, which prioritize immunoassay and chemistry testing according to each sample’s urgency.
June 2025—Qiagen announced the launch of its QIAprep& Plasmodium kit and two companion assays to support malaria research and surveillance efforts. The solution combines sample preparation and quantitative PCR into one workflow and detects all five Plasmodium species in human samples. The QIAprep& technology detects as little as one parasite per microliter, is compatible with liquid and dried blood samples, and is suitable for use on many qPCR platforms, including the company’s Rotor-Gene Q.
June 2025—Maine Molecular Quality Controls announced the release of the FilmArray TF control panel, for users of the FDA-cleared BioFire FilmArray tropical fever panel. The multiplexed control is intended for use as an external positive and negative assayed quality control to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of viral, bacterial, and parasitic pathogens. The kit includes six 200-μL positive controls and six 200-μL negative controls.
June 2025—Labcorp and North Mississippi Health Services announced that Labcorp has completed its acquisition of North Mississippi Health Services’ ambulatory outreach laboratory business and is now a referral laboratory for NMHS’ seven hospitals and clinic laboratories. In addition, Labcorp will open three patient service centers in Tupelo, West Point, and Amory by midyear to increase availability of laboratory services in North Mississippi.
June 2025—Diasorin announced it has received FDA 510(k) clearance for the Liaison Plex Gram-negative blood culture assay, the second of the company’s three multiplex molecular panels for blood culture pathogen identification on the Liaison Plex. The assay is designed to identify 27 targets—19 Gram-negative bacteria and eight relevant resistance gene targets, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Acinetobacter species, Citrobacter species, Enterobacter species, and Proteus species. Results are available about two hours after a Gram stain.
June 2025—Visby Medical announced it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its point-of-care Medical Respiratory Health test. The PCR test detects and differentiates between upper respiratory infections caused by influenza A and B and SARS-CoV-2 and provides results in less than 30 minutes.
June 2025—Mayo Clinic Laboratories and Kyan Technologies announced a collaboration to validate and provide Kyan’s Optim.AI across the United States. Optim.AI is an ex vivo drug sensitivity platform that combines small data AI and biological experiments. It provides insights into therapies for cancer patients and delivers efficiencies for cancer drug development. Mayo Clinic Labs will provide testing for physicians and researchers to support clinical and research decision-making for better treatment options.
June 2025—Thermo Fisher Scientific introduced new lines of floor-model centrifuges that feature natural refrigerant cooling systems compliant with European Union and U.S. Environmental Protection Agency fluorinated gas regulations. The Thermo Scientific Cryofuge, Bios, and Lynx centrifuges feature the company’s GreenCool technology, a next-generation natural refrigerant cooling system with a global warming potential of 1. Each model provides a reduction in energy consumption of up to 15 percent when compared with previous models.
June 2025—StatLab Medical Products announced that it is vertically integrating the production of containers and lids at its facility in Arlington, Tex., where the company currently produces nearly 100 million prefills annually, and will begin blow-molding gallon bottles in Q2. StatLab says it will also absorb any tariff-related fees associated with products manufactured in its European facilities when selling directly to U.S. laboratories. These products include PiSmart cassette and slide printers, KT microscope slides, and KT coverglass.
June 2025—Integrated DNA Technologies unveiled its xGen Hybridization and Wash version 3 kit. The kit features a high-throughput workflow that eliminates heated buffers and reduces hands-on time by 20 percent. The one-hour hybridization step delivers high-quality results and enables users to get from sample to sequencer in one day. The kit supports library inputs as low as 100 ng and pairs with xGen predesigned or custom Hyb panels and xGen Blocking Oligos.
